Fig. 2
From: Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis
A, B MG patients with acute aggravation were classified according to the guidelines of the MG Foundation of America (MGFA). TRAF6 expression exhibited an increasing trend from type I to type IV, although there was no statistical difference. C Correlation between the TRAF6 expression level in CD19+ B cells and the ADL score in OMG patients with acute aggravation (p < 0.001, r = 0.89) D Correlation between the TRAF6 expression level in CD19+ B cells and the ADL score in GMG patients with acute aggravation (p = 0.001, r = 0.59). E Correlation between the TRAF6 expression level in CD19+CD27+ memory B cells and the ADL score in OMG patients with acute aggravation (p = 0.001, r = 0.80). F Correlation between the TRAF6 expression level in CD19+CD27+ memory B cells and the ADL score in GMG patients with acute aggravation (p = 0.048, r = 0.38)